# PERSPECTIVE THERAPEUTICS, INC. (CATX) · Edgar & Edgarette company card

> Perspective Therapeutics (CATX) reported revenue of $1 million in FY2023, operating margin -2855% against a -3.8% median for pharmaceutical preparations, equity 76.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 728387 · fiscal year ended 2023-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CATX) · [JSON](https://www.pops4.com/boards/company/CATX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1M |
| Revenue growth, 1 year | — |
| Revenue growth per year | -42.0% |
| Operating margin | -2855.0% (prior year -Infinity%) |
| Net margin | -3243.2% |
| Operating cash flow | −$37M |
| Capital spending | $1M |
| Free cash flow | −$38M |
| Cash | $9M |
| Long-term debt | $2M |
| Total assets | $98M |
| Total equity | $75M |
| Equity ÷ assets | 76.8% |
| Return on equity | -61.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -4.33 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative (-$82.5M in FY2025); revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $1.4M (FY2023), total debt $1.7M. Experience: one year on record, down 42.0% a year over 4 years; operating margin -2855.0%, up from null. Soundness: equity 76.8% of assets, return on equity -61.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $550K and $987K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -2855.0% against a -3.8% median.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-10-23 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/728387/000119312526429770/0001193125-26-429770-index.htm)
- 8-K · filed 2026-10-08 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/728387/000119312526417384/0001193125-26-417384-index.htm)
- 8-K · filed 2026-10-01 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/728387/000119312526410663/0001193125-26-410663-index.htm)
- 8-K · filed 2026-09-14 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/728387/000119312526389785/0001193125-26-389785-index.htm)
- 8-K · filed 2026-09-08 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/728387/000119312526385362/0001193125-26-385362-index.htm)
- 10-Q · filed 2026-08-10 · [filing](https://www.sec.gov/Archives/edgar/data/728387/000119312526342512/0001193125-26-342512-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000728387.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=728387

## Cite

POPS4, Edgar & Edgarette: PERSPECTIVE THERAPEUTICS, INC. (CATX) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/CATX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2023, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.